Abstract
Predictive and prognostic testing for breast cancer is now an important part of cellular pathology. The UK National External Quality Assessment Scheme (NEQAS) for immunocytochemistry and fluorescent in situ hybridization plays a significant role in ensuring that the quality of testing meets the clinical standards required, by assessing the performance of each participant laboratory every 3 months. Besides receiving a confidential performance report, data on the methods used are collected, analysed against the scores and published in the UK NEQAS journal. This information is intended to help those who are not achieving the best scores to improve their performance.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
